Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT-ELIMINATE
NCT06499896Phase 2Withdrawn
- Start
- Jan 2027
- Primary completion
- Sep 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label trial of MTP-101 in immune-mediated colitis and immune-related dermatitis (2 cohorts). Primary endpoints: Incidence of adverse events at 2 months and Incidence of Dose-Limiting Toxicities at 2 months. Planned start Jan 2027; status: withdrawn.
02
Drugs
MTP-101
03
Conditions
immune-mediated colitisimmune-related dermatitis
Beyond the preview
Go deeper on NCT06499896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06499896.